Compare FITB & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FITB | NTRA |
|---|---|---|
| Founded | 1858 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2B | 32.9B |
| IPO Year | N/A | 2015 |
| Metric | FITB | NTRA |
|---|---|---|
| Price | $54.54 | $212.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 14 |
| Target Price | $53.88 | ★ $253.79 |
| AVG Volume (30 Days) | ★ 17.3M | 1.2M |
| Earning Date | 01-20-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 12.42 | N/A |
| EPS | ★ 3.53 | N/A |
| Revenue | ★ $8,355,000,000.00 | $2,116,676,000.00 |
| Revenue This Year | $55.13 | $33.95 |
| Revenue Next Year | $8.83 | $16.72 |
| P/E Ratio | $15.39 | ★ N/A |
| Revenue Growth | 5.09 | ★ 38.17 |
| 52 Week Low | $32.25 | $125.38 |
| 52 Week High | $55.36 | $256.36 |
| Indicator | FITB | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 68.05 | 38.84 |
| Support Level | $52.86 | $195.46 |
| Resistance Level | $55.35 | $236.58 |
| Average True Range (ATR) | 1.39 | 8.58 |
| MACD | 0.30 | -3.40 |
| Stochastic Oscillator | 86.39 | 30.57 |
Fifth Third Bancorp is a midsize regional bank in the US, with total assets of over $210 billion as of December 2025. The bank is set to close its acquisition of Comercia on Feb. 1, 2026. Headquartered in Cincinnati, Ohio, Fifth Third has a strong presence in the US Midwest and is currently expanding in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and Treasury management, wealth and asset management, and capital markets.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.